Boston Scientific Co. (NYSE:BSX) Stock Holdings Boosted by Pictet Asset Management Ltd.

Pictet Asset Management Ltd. raised its position in shares of Boston Scientific Co. (NYSE:BSX) by 27.2% in the second quarter, HoldingsChannel.com reports. The firm owned 3,063,568 shares of the medical equipment provider’s stock after buying an additional 655,860 shares during the period. Pictet Asset Management Ltd.’s holdings in Boston Scientific were worth $131,672,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BSX. Alps Advisors Inc. boosted its stake in shares of Boston Scientific by 12.2% during the 2nd quarter. Alps Advisors Inc. now owns 17,230 shares of the medical equipment provider’s stock worth $741,000 after acquiring an additional 1,874 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Boston Scientific by 2.2% during the second quarter. Charles Schwab Investment Management Inc. now owns 5,654,915 shares of the medical equipment provider’s stock worth $243,049,000 after acquiring an additional 119,294 shares in the last quarter. Cullen Frost Bankers Inc. raised its holdings in shares of Boston Scientific by 28.7% during the second quarter. Cullen Frost Bankers Inc. now owns 407,826 shares of the medical equipment provider’s stock worth $17,528,000 after acquiring an additional 90,900 shares in the last quarter. Somerset Group LLC raised its holdings in shares of Boston Scientific by 2.0% during the first quarter. Somerset Group LLC now owns 52,593 shares of the medical equipment provider’s stock worth $2,019,000 after acquiring an additional 1,052 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in shares of Boston Scientific during the first quarter worth $497,000. 91.47% of the stock is owned by hedge funds and other institutional investors.

NYSE BSX traded down $0.93 during trading on Tuesday, hitting $42.22. 4,050,014 shares of the company traded hands, compared to its average volume of 5,062,751. Boston Scientific Co. has a 12 month low of $31.56 and a 12 month high of $43.84. The business has a fifty day simple moving average of $42.40 and a 200 day simple moving average of $40.20. The company has a current ratio of 1.31, a quick ratio of 1.04 and a debt-to-equity ratio of 0.81. The company has a market capitalization of $60.65 billion, a P/E ratio of 28.72, a PEG ratio of 2.59 and a beta of 0.82.



Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.39 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.01. Boston Scientific had a return on equity of 23.29% and a net margin of 13.85%. The company had revenue of $2.63 billion for the quarter, compared to analyst estimates of $2.64 billion. During the same period last year, the company earned $0.41 earnings per share. The business’s revenue was up 5.7% compared to the same quarter last year. Equities research analysts predict that Boston Scientific Co. will post 1.56 EPS for the current fiscal year.

Several analysts recently issued reports on BSX shares. Piper Jaffray Companies set a $50.00 price objective on Boston Scientific and gave the stock a “buy” rating in a report on Wednesday, July 24th. Raymond James increased their price objective on Boston Scientific from $48.00 to $50.00 and gave the stock a “strong-buy” rating in a report on Thursday, July 25th. Barclays reiterated an “overweight” rating and set a $48.00 price objective on shares of Boston Scientific in a report on Tuesday, September 3rd. Stifel Nicolaus set a $47.00 price objective on Boston Scientific and gave the stock a “buy” rating in a report on Friday, September 6th. Finally, Leerink Swann set a $50.00 price objective on Boston Scientific and gave the stock a “buy” rating in a report on Wednesday, July 31st. Three equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $45.30.

In other news, EVP Joseph Michael Fitzgerald sold 20,673 shares of Boston Scientific stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $43.41, for a total value of $897,414.93. Following the transaction, the executive vice president now directly owns 226,835 shares in the company, valued at $9,846,907.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP David A. Pierce sold 5,000 shares of Boston Scientific stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $42.62, for a total value of $213,100.00. Following the completion of the transaction, the executive vice president now owns 29,201 shares in the company, valued at $1,244,546.62. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 82,671 shares of company stock worth $3,536,692. Corporate insiders own 0.66% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Article: 12b-1 Fees

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.